Therapeutic Targeting in Ovarian Cancer: Nano-Enhanced CRISPR/Cas9 Gene Editing and Drug Combination Therapy

Abstract Ovarian cancer is the third most common gynecological cancer worldwide. Due to the high recurrence rate of advanced-stage ovarian cancer, often resulting from drug-resistant and refractory disease, various treatment strategies are under investigation. Genome editing of therapeutic target genes holds promise in enhancing cancer treatment efficacy by elucidating gene functions and mechanisms involved in cancer progression. The CRISPR/Cas9 system, in particular, shows great potential in ovarian cancer gene therapy and drug development. Targeting therapeutic genes such as BRCA1/2, P53, Snai1 etc, could improve the therapeutic strategy in ovarian cancer. CRISPR/Cas9 is a powerful gene-editing tool that there are many on-going clinical trials to treat various diseases including cancer. Nano-based delivery systems for CRISPR/Cas9 offer further therapeutic benefits, leveraging the unique properties of nanoparticles to improve delivery efficiency. Nano-based delivery systems could enhance the stability of CRISPR/Cas9 delivery formats (such as plasmid, mRNA, etc) and improve the delivery precision of delivery to target tumors. Additionally, combining CRISPR/Cas9 with targeted drug treatments, especially those aimed at genes associated with drug resistance, may significantly improve therapeutic outcomes in ovarian cancer. In this review, we discuss therapeutic target genes and their mechanisms in ovarian cancer, advances in nano-based CRISPR/Cas9 delivery, and the therapeutic potential of combining CRISPR/Cas9 with drug treatments for ovarian cancer.

• Publication year

  2025

• Venue

  International Journal of Nanomedicine

• Publication date

  2025-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.2147/IJN.S507688PMID 40191042PMCID 11970428
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Affordable Pricing of CRISPR Treatments is a Pressing Ethical Imperative

  2024cited by this paper
• Development of Aptamer-DNAzyme based metal-nucleic acid frameworks for gastric cancer therapy

  2024cited by this paper
• Drug resistance in ovarian cancer: from mechanism to clinical trial

  2024cited by this paper
• Advanced strategies for CRISPR/Cas9 delivery and applications in gene editing, therapy, and cancer detection using nanoparticles and nanocarriers.

  2024cited by this paper
• An autocatalytic multicomponent DNAzyme nanomachine for tumor-specific photothermal therapy sensitization in pancreatic cancer

  2023cited by this paper
• CC Chemokine 2 Promotes Ovarian Cancer Progression through the MEK/ERK/MAP3K19 Signaling Pathway

  2023cited by this paper
• Therapeutic DNAzymes: From Structure Design to Clinical Applications

  2023cited by this paper
• Role of fibrilins in human cancer: A narrative review

  2023cited by this paper
• The multifaceted role of EGLN family prolyl hydroxylases in cancer: going beyond HIF regulation

  2022cited by this paper
• Interfering with the expression of EEF1D gene enhances the sensitivity of ovarian cancer cells to cisplatin

  2022cited by this paper
• Ovarian Cancer: Treatment and Resistance to Pharmacotherapy

  2022cited by this paper
• The roles and limitations of bevacizumab in the treatment of ovarian cancer

  2022cited by this paper
• Appropriate Selection of PARP Inhibitors in Ovarian Cancer

  2022cited by this paper
• Mechanisms of chemotherapy resistance in ovarian cancer

  2022cited by this paper
• Effect of ALDH1A1 Gene Knockout on Drug Resistance in Paclitaxel and Topotecan Resistant Human Ovarian Cancer Cell Lines in 2D and 3D Model

  2022cited by this paper
• RUNX1 and cancer.

  2022cited by this paper
• The Fibrillin‐1/VEGFR2/STAT2 signaling axis promotes chemoresistance via modulating glycolysis and angiogenesis in ovarian cancer organoids and cells

  2022cited by this paper
• Current Status of CRISPR/Cas9 Application in Clinical Cancer Research: Opportunities and Challenges

  2022cited by this paper
• Platinum-based drugs for cancer therapy and anti-tumor strategies

  2022cited by this paper
• Senescence induction dictates response to chemo- and immunotherapy in preclinical models of ovarian cancer

  2022cited by this paper
• Genome-wide CRISPR/Cas9 library screen identifies PCMT1 as a critical driver of ovarian cancer metastasis

  2022cited by this paper
• A Proton-Activatable DNA-Based Nanosystem Enables Co-Delivery of CRISPR/Cas9 and DNAzyme for Combined Gene Therapy.

  2022cited by this paper
• Treating ARID1A mutated cancers by harnessing synthetic lethality and DNA damage response

  2022cited by this paper
• CRISPR–Cas9: A History of Its Discovery and Ethical Considerations of Its Use in Genome Editing

  2022cited by this paper
• Tumor-Promoting ATAD2 and Its Preclinical Challenges

  2022cited by this paper
• CRISPR-mediated TGFBR2 knockout renders human ovarian cancer tumor-infiltrating lymphocytes resistant to TGF-β signaling

  2022cited by this paper
• Therapeutic Implications of FABP4 in Cancer: An Emerging Target to Tackle Cancer

  2022cited by this paper
• Effect of human endogenous retrovirus-K env gene knockout on proliferation of ovarian cancer cells

  2022cited by this paper
• Expression profiles of human endogenous retrovirus (HERV)-K and HERV-R Env proteins in various cancers

  2021cited by this paper
• The Roles of Human Endogenous Retroviruses (HERVs) in Inflammation

  2021cited by this paper
• Multiomic analysis identifies CPT1A as a potential therapeutic target in platinum-refractory, high-grade serous ovarian cancer

  2021cited by this paper
• Discovery of a Novel Amino Lipid That Improves Lipid Nanoparticle Performance through Specific Interactions with mRNA

  2021cited by this paper
• The role of EEF1D in disease pathogenesis: a narrative review

  2021cited by this paper
• Reduction-Sensitive Fluorinated-Pt(IV) Universal Transfection Nanoplatform Facilitating CT45-Targeted CRISPR/dCas9 Activation for Synergistic and Individualized Treatment of Ovarian Cancer.

  2021cited by this paper
• Genetic interactions among Brca1, Brca2, Palb2, and Trp53 in mammary tumor development

  2021cited by this paper
• Ovarian Cancer Treatments Strategy: Focus on PARP Inhibitors and Immune Check Point Inhibitors

  2021cited by this paper
• Knockout of vasohibin‐2 reduces tubulin carboxypeptidase activity and increases paclitaxel sensitivity in ovarian cancer

  2021cited by this paper
• A systematic review and meta-analysis

  2021cited by this paper
• Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

  2021cited by this paper
• A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin

  2021cited by this paper
• The CRISPR-Cas Mechanism for Adaptive Immunity and Alternate Bacterial Functions Fuels Diverse Biotechnologies

  2021cited by this paper
• Taxanes in cancer treatment: Activity, chemoresistance and its overcoming.

  2021cited by this paper
• PAR2 induces ovarian cancer cell motility by merging three signalling pathways to transactivate EGFR

  2020cited by this paper
• CRISPR-Cas9 genome editing using targeted lipid nanoparticles for cancer therapy

  2020cited by this paper
• Therapy Resistance, Cancer Stem Cells and ECM in Cancer: The Matrix Reloaded

  2020cited by this paper
• Immunotherapy for Ovarian Cancer: Adjuvant, Combination, and Neoadjuvant

  2020cited by this paper
• Knockout of EGFL6 by CRISPR/Cas9 Mediated Inhibition of Tumor Angiogenesis in Ovarian Cancer

  2020cited by this paper
• The potent roles of salt-inducible kinases (SIKs) in metabolic homeostasis and tumorigenesis

  2020cited by this paper
• CRISPR Gene Therapy: Applications, Limitations, and Implications for the Future

  2020cited by this paper
• Inhibition of RUNX1 Promotes Cisplatin-induced Apoptosis in Ovarian Cancer Cells.

  2020cited by this paper
• Application of Various Delivery Methods for CRISPR/dCas9

  2020cited by this paper
• The emerging role of EGFL6 in angiogenesis and tumor progression

  2020cited by this paper
• CCL2/CCR2 signaling in cancer pathogenesis

  2020cited by this paper
• Therapeutic Nanoparticles and Their Targeted Delivery Applications

  2020cited by this paper
• EMT Factors and Metabolic Pathways in Cancer

  2020cited by this paper
• Nanoparticles-mediated CRISPR/Cas9 delivery: Recent advances in cancer treatment

  2020cited by this paper
• Exonuclease 1 (Exo1) Participates in Mammalian Non-Homologous End Joining and Contributes to Drug Resistance in Ovarian Cancer

  2020cited by this paper
• Adipocyte-Induced FABP4 Expression in Ovarian Cancer Cells Promotes Metastasis and Mediates Carboplatin Resistance

  2020cited by this paper
• Mechanism and current progress of Poly ADP-ribose polymerase (PARP) inhibitors in the treatment of ovarian cancer.

  2020cited by this paper
• STAT3 signaling in ovarian cancer: a potential therapeutic target

  2020cited by this paper
• CPT1A-mediated fat oxidation, mechanisms and therapeutic potential.

  2020cited by this paper
• PARP inhibitors in ovarian cancer: Sensitivity prediction and resistance mechanisms

  2019cited by this paper
• CRISPR/Cas9 for overcoming drug resistance in solid tumors

  2019cited by this paper
• Programmed cell death ligand 1 disruption by clustered regularly interspaced short palindromic repeats/Cas9‐genome editing promotes antitumor immunity and suppresses ovarian cancer progression

  2019cited by this paper
• CRISPR/Cas9: a powerful tool for identification of new targets for cancer treatment.

  2019cited by this paper
• Ovarian Cancer: An Integrated Review.

  2019cited by this paper
• Genome-Wide Interrogation of Human Cancers Identifies EGLN1 Dependency in Clear Cell Ovarian Cancers.

  2019cited by this paper
• A Novel ALDH1A1 Inhibitor Targets Cells with Stem Cell Characteristics in Ovarian Cancer

  2019cited by this paper
• Rgnef promotes ovarian tumor progression and confers protection from oxidative stress

  2019cited by this paper
• Multi-omics profiling reveals key signaling pathways in ovarian cancer controlled by STAT3

  2019cited by this paper
• Therapeutic preferability of gemcitabine for ARID1A-deficient ovarian clear cell carcinoma.

  2019cited by this paper
• Non-viral delivery of CRISPR/Cas9 complex using CRISPR-GPS nanocomplexes.

  2019cited by this paper
• ATAD2 predicts poor outcomes in patients with ovarian cancer and is a marker of proliferation

  2019cited by this paper
• B7-H3 Induces Ovarian Cancer Drugs Resistance Through An PI3K/AKT/BCL-2 Signaling Pathway

  2019cited by this paper
• Knockout of MTF1 Inhibits the Epithelial to Mesenchymal Transition in Ovarian Cancer Cells

  2018cited by this paper
• Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

  2018cited by this paper
• Cancer of the ovary, fallopian tube, and peritoneum

  2018cited by this paper
• Multi-level Proteomics Identifies CT45 as a Chemosensitivity Mediator and Immunotherapy Target in Ovarian Cancer.

  2018cited by this paper
• In Vivo Ovarian Cancer Gene Therapy Using CRISPR-Cas9

  2018cited by this paper
• CRISPR-Cas guides the future of genetic engineering

  2018cited by this paper
• Molecular biology at the cutting edge: A review on CRISPR/CAS9 gene editing for undergraduates

  2018cited by this paper
• Role of BMI1 in epithelial ovarian cancer: investigated via the CRISPR/Cas9 system and RNA sequencing

  2018cited by this paper
• Molecular mechanisms of drug resistance in ovarian cancer

  2018cited by this paper
• Engineering the Delivery System for CRISPR-Based Genome Editing.

  2018cited by this paper
• Counterpoint: The Potential Harms of Human Gene Editing Using CRISPR-Cas9.

  2018cited by this paper
• Gene Editing and Crop Improvement Using CRISPR-Cas9 System

  2017cited by this paper
• Lentiviral CRISPR/Cas9 nickase vector mediated BIRC5 editing inhibits epithelial to mesenchymal transition in ovarian cancer cells

  2017cited by this paper
• Artificial Virus Delivers CRISPR-Cas9 System for Genome Editing of Cells in Mice.

  2017cited by this paper
• Lentiviral CRISPR/Cas9 vector mediated miR-21 gene editing inhibits the epithelial to mesenchymal transition in ovarian cancer cells

  2017cited by this paper
• Knockdown of EPHA1 Using CRISPR/CAS9 Suppresses Aggressive Properties of Ovarian Cancer Cells.

  2017cited by this paper
• CRISPR-Cas9: From a bacterial immune system to genome-edited human cells in clinical trials

  2017cited by this paper
• Non-homologous DNA end joining and alternative pathways to double-strand break repair

  2017cited by this paper
• Methods for decoding Cas9 protospacer adjacent motif (PAM) sequences: A brief overview.

  2017cited by this paper
• Emerging Therapeutics to Overcome Chemoresistance in Epithelial Ovarian Cancer: A Mini-Review

  2017cited by this paper
• CRISPR/Cas9-derived models of ovarian high grade serous carcinoma targeting Brca1, Pten and Nf1, and correlation with platinum sensitivity

  2017cited by this paper
• Vasohibins encode tubulin detyrosinating activity

  2017cited by this paper
• CRISPR-Cas9 Structures and Mechanisms.

  2017cited by this paper
• Nanotechnology as a Promising Strategy for Anticancer Drug Delivery.

  2017cited by this paper
• Survivin: a unique target for tumor therapy

  2016cited by this paper
• CRISPR/Cas9-Mediated Trp53 and Brca2 Knockout to Generate Improved Murine Models of Ovarian High-Grade Serous Carcinoma.

  2016cited by this paper

• Unraveling the role of M2 TAMs in ovarian cancer dynamics: a systematic review

  2025cites this paper
• Targeting super-enhancers in liver cancer: from pathogenic mechanisms to clinical applications

  2025cites this paper
• Therapeutic Potential and Clinical Translation of Nanodrugs: A Path Forward- Case Studies from Bench to Bedside

  2025cites this paper
• Natural products in the treatment of osteoarthritis: Current status and prospects

  2025cites this paper
• Investigation of CT imaging-based Bi2S3 drug-loaded nanoparticles for the diagnosis and therapy of colorectal cancer.

  2025cites this paper
• Crosstalk between microRNA and oxidative stress in ovarian cancer: diagnosis, pathogenesis and therapeutic resistance

  2025cites this paper